HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Attenuation by cyclic phosphatidic acid of peritoneal metastasis of azoxymethane-induced intestinal cancers in Wistar rats.

Abstract
The effect of cyclic phosphatidic acid, a unique analogue of lysophosphatidic acid, on the induction of bombesin-enhanced peritoneal metastases from intestinal adenocarcinomas induced by azoxymethane was investigated in male Wistar rats. Rats were given 10 weekly injections of azoxymethane (7.4 mg/kg body weight, s.c.) and of bombesin (40 microg/kg body weight, s.c.) every other day from the start of the experiment, and from week 16, they received injections of cyclic phosphatidic acid (3 or 6 mg/kg body weight, s.c.) every other day until the end of the experiment in week 45. Cyclic phosphatidic acid at both dosages significantly decreased the incidence of bombesin-enhanced cancer metastases to the peritoneum but had little or no effect on the location, histologic type, depth of involvement or infiltrating growth patterns of the tumors. Cyclic phosphatidic acid at either dose decreased significantly the incidence of lymphatic vessel invasion of adenocarcinomas and the activity of RhoA protein in the tumors, both of which were enhanced by bombesin. Our findings indicate that cyclic phosphatidic acid inhibits cancer metastasis through inhibition of RhoA protein activation.
AuthorsRyu Ishihara, Masaharu Tatsuta, Hiroyasu Iishi, Miyako Baba, Noriya Uedo, Koji Higashino, Mutsuko Mukai, Shingo Ishiguro, Susumu Kobayashi, Kimiko Murakami-Murofushi
JournalInternational journal of cancer (Int J Cancer) Vol. 110 Issue 2 Pg. 188-93 (Jun 10 2004) ISSN: 0020-7136 [Print] United States
PMID15069680 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2004 Wiley-Liss, Inc.
Chemical References
  • Lysophospholipids
  • Cyclic AMP
  • rhoA GTP-Binding Protein
  • Azoxymethane
Topics
  • Adenocarcinoma (drug therapy, pathology)
  • Animals
  • Azoxymethane
  • Cyclic AMP (biosynthesis)
  • Intestinal Neoplasms (chemically induced, drug therapy, pathology)
  • Lysophospholipids (pharmacology, therapeutic use)
  • Male
  • Neoplasm Invasiveness
  • Peritoneal Neoplasms (prevention & control, secondary)
  • Rats
  • Rats, Wistar
  • rhoA GTP-Binding Protein (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: